Word: estrogenous
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors...
...comes word that another estrogen-like drug, called raloxifene, is as effective as tamoxifen at reducing the risk of breast cancer--at least in high-risk, postmenopausal women--with fewer of those side effects. According to preliminary results from the Study of Tamoxifen and Raloxifene (STAR), raloxifene triggered fewer uterine cancers, blood clots and hot flashes than tamoxifen. It also decreased the chances of developing cataracts...
...tricky. A closer look at the findings shows that women who have had a benign breast ailment, who score high on the so-called Gail model of breast-cancer risks or whose mother or sister had breast cancer are slightly more likely to develop breast cancer when taking estrogen supplements. In addition, all study participants, regardless of their breast-cancer risk, were more likely to have suspicious-looking mammograms that required biopsies to make sure that nothing was wrong...
...have severe menopausal symptoms, have lost your uterus and don't have a high risk of developing breast cancer or blood clots, you can safely consider estrogen therapy for temporary relief. Eventually, as genetic tests based on blood samples from WHI participants start to be developed, investigators should be able to say even more precisely who is likely to benefit from estrogen treatment and who should avoid it. Meanwhile, stay tuned for more surprising WHI results...
...said in a press release. Winer and his colleagues from institutions around the country reexamined three past breast cancer studies, each of which spanned a separate five-year period, beginning in 1985. The researchers compared the responses to chemotherapy of women whose tumors were sensitive to the hormone estrogen (ER-positive) and women whose tumors were not sensitive to estrogen (ER-negative). The researchers examined how evolving treatment regimens have affected the relapse and death rates of study participants. The researchers found that lower relapse and death rates correlated to improvements in chemotherapy for ER-negative patients. Chemotherapy increased...